Nuvalent (NUVL): A Closer Look at Valuation as New ALK Inhibitor Data Presentation Approaches [Yahoo! Finance]
Nuvalent, Inc. - Class A (NUVL)
NASDAQ:AMEX Investor Relations:
nuvelinc.com/company/investor_relations.html
Company Research
Source: Yahoo! Finance
The presentation will focus on an investigational ALK-selective inhibitor for advanced non-small cell lung cancer. This update is drawing attention from investors. See our latest analysis for Nuvalent. Nuvalent's momentum has been hard to miss, with recent clinical updates and positive analyst coverage fueling a 26.9% share price return over the past 90 days. While the 1-year total shareholder return stands at just 11.1%, the three-year figure tells a much more impressive growth story at over 200%. This highlights how recent milestones are renewing confidence among investors seeking long-term potential. If you're curious about where biotech innovation is heading next, this could be the perfect time to explore See the full list for free. Despite robust analyst enthusiasm and a share price still trading nearly 30% below the consensus price target, the question remains: is Nuvalent undervalued at its current levels, or is the market already accounting for its expected future gain
Show less
Read more
Impact Snapshot
Event Time:
NUVL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVL alerts
High impacting Nuvalent, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
NUVL
News
- Does Nuvalent's Recent Trial Success Justify the Stock's 36% 2025 Rally? [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- Nuvalent Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares from Selling StockholdersPR Newswire
- Nuvalent (NASDAQ:NUVL) was given a new $140.00 price target on by analysts at Truist Financial Corporation.MarketBeat
NUVL
Earnings
- 5/8/25 - Miss
NUVL
Sec Filings
- 12/2/25 - Form 4
- 11/26/25 - Form 4
- 11/24/25 - Form 4
- NUVL's page on the SEC website